文献速递妇科

比较「所有患者使用PARP抑制剂」与基于生物标志物指导的PARP抑制剂维持治疗在新诊断晚期卵巢癌中的成本-效果分析

Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-08-27

本研究采用改良马尔可夫决策模型模拟PRIMA、VELIA和PAOLA-1试验设计,比较「所有患者使用PARP抑制剂」与基于生物标志物指导的维持治疗策略的成本-效果。结果显示PARPi-for-all策略成本更高且PFS获益更大,ICER分别为每获得一个质量调整无进展生命年593,250美元(PRIMA)、1,512,495美元(VELIA)和3,347,915美元(PAOLA-1);在当前药价下,生物标志物阴性队列中无PFS改善可使PARPi-for-all相比生物标志物指导策略具有成本-效果。

要点

  • PARPi-for-all策略在三个模型中均比生物标志物指导策略成本更高且PFS获益更大。
  • ICER分别为593,250美元/QA-PFY(PRIMA)、1,512,495美元/QA-PFY(VELIA)、3,347,915美元/QA-PFY(PAOLA-1)。
  • 在当前药价下,生物标志物阴性队列中无PFS改善可使PARPi-for-all具有成本-效果。

核心结论

  • 本研究强调与生物标志物指导的PARP抑制剂策略相比,所有患者使用PARP抑制剂维持治疗的成本很高。
  • 作者认为一线维持治疗应保留给具有胚系或体细胞HRD突变的患者,直到治疗成本显著降低。

研究设计与样本

  • 采用改良马尔可夫决策模型模拟PRIMA、VELIA和PAOLA-1试验设计,比较PARPi-for-all与生物标志物指导维持治疗策略的成本。
  • 感兴趣结局包括总成本和以美元/质量调整无进展生命年(QA-PFY)报告的增量成本-效果比(ICER)。

主要发现

  • PARPi-for-all策略每位患者的平均成本在PRIMA、VELIA和PAOLA-1模型中分别为166,269美元、286,715美元和366,506美元。
  • 生物标志物指导策略每位患者的平均成本在PRIMA、VELIA和PAOLA-1模型中分别为98,188美元、167,334美元和260,671美元。
  • PARPi-for-all相比生物标志物指导维持治疗的ICER分别为593,250美元/QA-PFY(PRIMA)、1,512,495美元/QA-PFY(VELIA)和3,347,915美元/QA-PFY(PAOLA-1)。
  • 在当前药价下,生物标志物阴性队列中无PFS改善可使PARPi-for-all相比生物标志物指导维持治疗具有成本-效果。

临床怎么用

  • 作者认为一线维持治疗应保留给具有胚系或体细胞HRD突变的患者,直到治疗成本显著降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical trials evaluating universal PARP inhibitor (PARPi) frontline maintenance therapy for advanced stage ovarian cancer have reported progression-free survival (PFS) benefit. It is unclear whether PARPi maintenance therapy will universally enhance value (clinical benefits relative to cost of delivery). We compared a "PARPi-for-all" to a biomarker-directed frontline maintenance therapy approach as a value-based care strategy. METHODS: The cost of two frontline PARPi maintenance strategies, PARPi-for-all and biomarker-directed maintenance, was compared using modified Markov decision models simulating the study designs of the PRIMA, VELIA, and, PAOLA-1 trials. Outcomes of interest included overall costs and incremental cost-effectiveness ratios (ICERs) reported in US dollars per quality adjusted progression-free life-year (QA-PFY) gained. RESULTS: PARPi-for-all was more costly and provided greater PFS benefit than a biomarker-directed strategy for each trial. The mean cost per patient for the PARPi-for-all strategy was $166,269, $286,715, and $366,506 for the PRIMA, VELIA, and PAOLA-1 models, respectively. For the biomarker-directed strategy, the mean cost per patient was $98,188, $167,334, and $260,671 for the PRIMA, VELIA, and PAOLA-1 models. ICERs of PARPi-for-all compared to biomarker-directed maintenance were: $593,250/QA-PFY (PRIMA), $1,512,495/QA-PFY (VELIA), and $3,347,915/QA-PFY (PAOLA-1). At current drug pricing, there is no PFS improvement in a biomarker negative cohort that would make PARPi-for-all cost-effective compared to biomarker-directed maintenance. CONCLUSIONS: This study highlights the high costs of universal PARPi maintenance treatment, compared with a biomarker-directed PARPi strategy. Maintenance therapy in the front-line setting should be reserved for those with germline or somatic HRD mutations until the cost of therapy is significantly reduced.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gonzalez R, Havrilesky LJ, Myers ER, et al. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol. 2020. PMID: 32863036. doi:10.1016/j.ygyno.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。